^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Conmana (icotinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
Published date:
07/09/2020
Excerpt:
...we report a patient diagnosed with lung adenocarcinoma harboring EGFR 19Del/T790M/in trans-C797S mutations with co-occurring CTNNB1 alteration showing a negative response to combination therapy with first- and third-generation TKIs….he started on icotinib as first line treatment in November 2014. According to the criteria of response evaluation criteria in solid tumors (RECIST) version 1.1, best response during the first line was partial response (PR). After 18 months duration time with icotinib, progressive disease (PD) of the primary lesion in lung, as well as pleural effusion was detected with chest CT in May, 2016.
DOI:
10.2147/OTT.S262594
